
Wenan Qiang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/32892/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17053-17058.	7.1	148
2	MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Modern Pathology, 2014, 27, 1144-1153.	5.5	138
3	Role of Stem Cells in Human Uterine Leiomyoma Growth. PLoS ONE, 2012, 7, e36935.	2.5	126
4	Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors. Molecular Cancer Research, 2019, 17, 70-83.	3.4	83
5	Activation of Transcription Factor Nrf-2 and Its Downstream Targets in Response to Moloney Murine Leukemia Virus ts 1-Induced Thiol Depletion and Oxidative Stress in Astrocytes. Journal of Virology, 2004, 78, 11926-11938.	3.4	78
6	ATM deficiency induces oxidative stress and endoplasmic reticulum stress in astrocytes. Laboratory Investigation, 2005, 85, 1471-1480.	3.7	77
7	Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma. Cancer, 2014, 120, 3165-3177.	4.1	71
8	Human Uterine Leiomyoma Stem/Progenitor Cells Expressing CD34 and CD49b Initiate Tumors In Vivo. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E601-E606.	3.6	65
9	Down-Regulation of miR-29b Is Essential for Pathogenesis of Uterine Leiomyoma. Endocrinology, 2014, 155, 663-669.	2.8	62
10	Anti- <i>miR182</i> Reduces Ovarian Cancer Burden, Invasion, and Metastasis: An <i>In Vivo</i> Study in Orthotopic Xenografts of Nude Mice. Molecular Cancer Therapeutics, 2014, 13, 1729-1739.	4.1	55
11	Mammalian Pum1 and Pum2 Control Body Size via Translational Regulation of the Cell Cycle Inhibitor Cdkn1b. Cell Reports, 2019, 26, 2434-2450.e6.	6.4	51
12	Possible involvement of both endoplasmic reticulum– and mitochondria-dependent pathways in MoMuLV-ts1–induced apoptosis in astrocytes. Journal of NeuroVirology, 2004, 10, 189-198.	2.1	48
13	Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells. Oncotarget, 2017, 8, 94666-94680.	1.8	45
14	Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. Breast Cancer Research, 2019, 21, 137.	5.0	42
15	MK-2206, an AKT Inhibitor, Promotes Caspase-Independent Cell Death and Inhibits Leiomyoma Growth. Endocrinology, 2013, 154, 4046-4057.	2.8	41
16	Activation of endoplasmic reticulum stress signaling pathway is associated with neuronal degeneration in MoMuLV-ts1-induced spongiform encephalomyelopathy. Laboratory Investigation, 2004, 84, 816-827.	3.7	40
17	Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma. Journal of Hematology and Oncology, 2016, 9, 92.	17.0	40
18	The peroxisome proliferator phenylbutyric acid (PBA) protects astrocytes from ts 1 MoMuLV-induced oxidative cell death. Journal of NeuroVirology, 2002, 8, 318-325.	2.1	38

Wenan Qiang

#	Article	IF	CITATIONS
19	Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells. Oncotarget, 2015, 6, 38983-38998.	1.8	38
20	Retrovirus-Induced Oxidative Stress with Neuroimmunodegeneration Is Suppressed by Antioxidant Treatment with a Refined Monosodium α-Luminol (Galavit). Journal of Virology, 2006, 80, 4557-4569.	3.4	35
21	Subtype-Specific Tumor-Associated Fibroblasts Contribute to the Pathogenesis of Uterine Leiomyoma. Cancer Research, 2017, 77, 6891-6901.	0.9	33
22	Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models. Translational Oncology, 2017, 10, 669-678.	3.7	32
23	The ataxiaâ€ŧelangiectasia gene product may modulate DNA turnover and control cell fate by regulating cellular redox in lymphocytes. FASEB Journal, 2001, 15, 1132-1138.	0.5	31
24	Interaction between endoplasmic reticulum stress and caspase 8 activation in retrovirus MoMuLV-ts1-infected astrocytes. Virology, 2006, 348, 398-405.	2.4	30
25	Astrocytes Survive Chronic Infection and Cytopathic Effects of the ts 1 Mutant of the Retrovirus Moloney Murine Leukemia Virus by Upregulation of Antioxidant Defenses. Journal of Virology, 2006, 80, 3273-3284.	3.4	30
26	Inactivation of AKT Induces Cellular Senescence in Uterine Leiomyoma. Endocrinology, 2014, 155, 1510-1519.	2.8	28
27	HMGA2-mediated tumorigenesis through angiogenesis in leiomyoma. Fertility and Sterility, 2020, 114, 1085-1096.	1.0	27
28	Induction of p53 Accumulation by Moloney Murine Leukemia Virus-ts1 Infection in Astrocytes Via Activation of Extracellular Signal-Regulated Kinases 1/2. Laboratory Investigation, 2002, 82, 693-702.	3.7	24
29	Anti-inflammatory activities of Sigesbeckia glabrescens Makino: combined in vitro and in silico investigations. Chinese Medicine, 2019, 14, 35.	4.0	23
30	ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice. Gastroenterology, 2020, 159, 289-305.e16.	1.3	22
31	Up-regulation of astrocyte cyclooxygenase-2, CCAAT/enhancer-binding protein, glucose-related protein 78, eukaryotic initiation factor 21±, and c-Jun N-terminal kinase by a neurovirulent murine retrovirus. Journal of NeuroVirology, 2005, 11, 166-179.	2.1	20
32	Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC). Critical Reviews in Oncology/Hematology, 2020, 145, 102856.	4.4	17
33	Prevention of thymic lymphoma development in Atm-/- mice by dexamethasone. Cancer Research, 2002, 62, 5153-7.	0.9	17
34	Enhanced proteolysis of llºBα and llºBβ proteins in astrocytes by Moloney murine leukemia virus (MoMuLV)- ts 1 infection: A potential mechanism of NF-κB activation. Journal of NeuroVirology, 2001, 7, 466-475.	2.1	16
35	ATM controls c-Myc and DNA synthesis during postnatal thymocyte development through regulation of redox state. Free Radical Biology and Medicine, 2006, 41, 640-648.	2.9	15
36	Chinese Herbs Interfering with Cancer Reprogramming Metabolism. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-10.	1.2	12

WENAN QIANG

#	Article	IF	CITATIONS
37	<i>Pumilio2</i> regulates synaptic plasticity via translational repression of synaptic receptors in mice. Oncotarget, 2018, 9, 32134-32148.	1.8	12
38	Halofuginone suppresses growth of human uterine leiomyoma cells in a mouse xenograft model. Human Reproduction, 2016, 31, 1540-1551.	0.9	11
39	Cellular kinetics of MED12-mutant uterine leiomyoma growth and regression in vivo. Endocrine-Related Cancer, 2018, 25, 747-759.	3.1	11
40	Control of Atm?/? thymic lymphoma cell proliferation in vitro and in vivo by dexamethasone. Cancer Chemotherapy and Pharmacology, 2005, 55, 203-212.	2.3	10
41	Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma. Oncogene, 2021, 40, 3273-3286.	5.9	8
42	Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer. Cancers, 2022, 14, 79.	3.7	7
43	A small molecule inhibitor of the perinucleolar compartment, ML246, attenuates growth and spread of ovarian cancer. Gynecologic Oncology Research and Practice, 2018, 5, 7.	3.6	6
44	HE4 and eIF3a Expression Correlates with Surgical Outcome and Overall Survival in Ovarian Cancer Patients with Secondary Cytoreduction. Journal of Cancer, 2018, 9, 2472-2479.	2.5	4
45	Correlation between different levels of HER2 expression in circulating tumor cells (cHER2 ratio) and metastatic behavior in stageIV _{aggressive} breast cancer Journal of Clinical Oncology, 2021, 39, 3036-3036.	1.6	3
46	lodide Analogs of Arsenoplatins—Potential Drug Candidates for Triple Negative Breast Cancers. Molecules, 2021, 26, 5421.	3.8	3
47	Proteolytic pan-RAS Cleavage Leads to Tumor Regression in Patient-derived Pancreatic Cancer Xenografts. Molecular Cancer Therapeutics, 2022, 21, 810-820.	4.1	2
48	Abstract P2-02-05: Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer. Cancer Research, 2022, 82, P2-02-05-P2-02-05.	0.9	0
49	Abstract P2-01-04: Esr1 hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer. Cancer Research, 2022, 82, P2-01-04-P2-01-04.	0.9	0
50	Abstract P2-01-08: <i>Esr1</i> Y537 mutations are associated with increased baseline circulating tumor cells enumeration for patients with estrogen receptor positive metastatic breast cancer. Cancer Research, 2022, 82, P2-01-08-P2-01-08.	0.9	0